Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: June 2014

4 - Medical management of excessive menstrual bleeding

References

1. Hospital episode statistics (HES) online. Main procedures and interventions: 3 character [http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=205].
2. National Institute for Health and Clinical Excellence. Heavy Menstrual Bleeding: Investigation and Treatment. Clinical guideline 44. London; NICE: 2007 [http://www.nice.org.uk/guidance/CG44].
3. OehlerMK, ReesMC. Menorrhagia: an update. Acta Obstet Gynecol Scand 2003;82:405–22.
4. NHS Evidence. Clinical Knowledge Summaries: Menorrhagia [http://www.cks.library.nhs.uk/menorrhagia].
6. LethabyA, AugoodC, DuckittK, FarquharC. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2007;(4):CD000400.
7. LethabyA, FarquharC, CookeI. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2007;CD000249.
8. NaoulouB, TsaiMC. Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: A systematic review. Acta Obstet Gynecol Scand. 2012 Jan 10. doi: 10.1111/j.1600–0412.2012.01361.x. [Epub ahead of print].
9. LethabyAE, CookeI, ReesM. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005;(4):CD002126.
10. LethabyA, IrvineG, CameronI. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008;(1):CD001016.
11. RobertsTE, TsourapasA, MiddletonLJ. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ 2011;342:d2202.
12. BhattacharyaS, MiddletonLJ, TsourapasA, et al.; International Heavy Menstrual Bleeding Individual Patient Data Meta-analysis Collaborative Group. Hysterectomy, endometrial ablation and Mirena® for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis. Health Technol Assess 2011;15:iii–xvi, 1–252.
13. KaunitzAM, MeredithS, InkiP, KubbaA, Sanchez-RamosL. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009;113:1104–16.
14. WildemeerschD. Intrauterine drug delivery for contraception and gynaecological treatment: novel approaches. Handb Exp Pharmacol 2010;197:267–98.
15. HurskainenR, TeperiJ, RissanenP, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004;291:1456–63.
16. LeminenH, Heliövaara-PeippoS, HalmesmäkiK, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on premenstrual symptoms in women treated for menorrhagia: secondary analysis of a randomised controlled trial. Acta Obstet Gynecol Scand 2012;91:279–400.
17. VasilakisC, JickH, del Mar Melero-MontesM. Risk of idiopathic venous thromboembolism in users of progestogens alone. Lancet 1999;354:1610–11.
18. MaguireK, WesthoffC. The state of hormonal contraception today: established and emerging noncontraceptive health benefits. Am J Obstet Gynecol 2011;205(4 Suppl):S4–8.
19. MicksE, JensenJT. Estradiol valerate and dienogest: a novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding. Womens Health (Lond Engl) 2011;7:513–24.
20. BeaumontH, AugoodC, DuckittK, LethabyA. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev 2007;(3):CD001017.
21. BrownA, ChengL, LinS, BairdDT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87:63–70.
22. EisingerSH, BonfiglioT, FiscellaK, MeldrumS, GuzickDS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12:227–33.
23. WilkensJ, ChwaliszK, HanC, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008;93:4664–71.
24. DonnezJ, TatarchukTF, BouchardP, et al.; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409–20.
25. DonnezJ, TomaszewskiJ, VázquezF, et al.; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421–32.
26. KennedyAD, SculpherMJ, CoulterA, DwyerN, ReesM, AbramsKR, et al. Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. JAMA 2002;288:2701–8.